Flizasertib

Overview

Flizasertib (GDC-8264) is an orally active, reversible and selective RIP1 inhibitor with K i app values of 0.00071 μM and 0.0013 μM for human and cynomolgus monkey RIP1 kinase, respectively. Flizasertib blocks RIP1 autophosphorylation but does not affect RIP1 protein stability. Flizasertib inhibits pro-inflammatory cytokines ( CCL3 , CCL4 , and IL-1β ) production. Flizasertib results in inhibition of colitis and ileitis. Flizasertib can be used in the research of cardiac surgery-associated acute kidney injury.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Renal Disease | Products > Disease Areas > Colitis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-152846
• CAS No.: 2268739-68-8
• Molecular Formula: C15H14FN3O
• Molecular Weight: 271.29
• Purity: 99.9%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source